-
Something wrong with this record ?
Impaired intestinal permeability in patients with multiple sclerosis
L. Fialova, P. Barilly, I. Stetkarova, A. Bartos, L. Noskova, D. Zimova, M. Zido, I. Hoffmanova
Language English Country Czech Republic
Document type Journal Article
NLK
Directory of Open Access Journals
from 2001
Free Medical Journals
from 1998
Medline Complete (EBSCOhost)
from 2007-06-01
ROAD: Directory of Open Access Scholarly Resources
from 2001
PubMed
37581230
DOI
10.5507/bp.2023.033
Knihovny.cz E-resources
- MeSH
- Biomarkers * blood MeSH
- Claudin-3 * metabolism MeSH
- Adult MeSH
- Intestinal Barrier Function MeSH
- Middle Aged MeSH
- Humans MeSH
- Permeability * MeSH
- Fatty Acid-Binding Proteins * blood MeSH
- Multiple Sclerosis * physiopathology metabolism blood MeSH
- Intestinal Mucosa metabolism MeSH
- Case-Control Studies MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: A number of recent studies have shown that the intestinal microbiome, part of the brain-gut axis, is implicated in the pathophysiology of multiple sclerosis. An essential part of this axis, is the intestinal barrier and gastrointestinal disorders with intestinal barrier dysregulation appear to be linked to CNS demyelination, and hence involved in the etiopathogenesis of multiple sclerosis (MS). OBJECTIVE: The aim of this study was to evaluate the integrity of the intestinal barrier in patients with clinically definite multiple sclerosis (CDMS) and clinically isolated syndrome (CIS) using two serum biomarkers, claudin-3 (CLDN3), a component of tight epithelial junctions, and intestinal fatty acid binding protein (I-FABP), a cytosolic protein in enterocytes. METHODS: Serum levels of CLDN3 in 37 MS patients and 22 controls, and serum levels of I-FABP in 46 MS patients and 51 controls were measured using commercial ELISA kits. Complete laboratory tests excluded the presence of gluten-related disorders in all subjects. Thirty MS patients received either disease-modifying drugs (DMD), immunosuppression (IS) or corticosteroid treatment. RESULTS: CLDN3 levels were only significantly higher in the MS patients treated with DMD or IS compared to the control group (P=0.006). There were no differences in I-FABP serum levels between the groups. Serum CLDN3 levels did not correlate with serum I-FABP levels in CDMS, in CIS patients or controls. CONCLUSIONS: In multiple sclerosis patients, the intestinal epithelium may be impaired with increased permeability, but without significant enterocyte damage characterized by intracellular protein leakage. Based on our data, CLDN3 serum levels appear to assess intestinal dysfunction in MS patients but mainly in treated ones.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25008986
- 003
- CZ-PrNML
- 005
- 20250522101940.0
- 007
- ta
- 008
- 250411s2025 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.5507/bp.2023.033 $2 doi
- 035 __
- $a (PubMed)37581230
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Fialová, Lenka, $d 1957- $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic $7 xx0074272
- 245 10
- $a Impaired intestinal permeability in patients with multiple sclerosis / $c L. Fialova, P. Barilly, I. Stetkarova, A. Bartos, L. Noskova, D. Zimova, M. Zido, I. Hoffmanova
- 520 9_
- $a BACKGROUND: A number of recent studies have shown that the intestinal microbiome, part of the brain-gut axis, is implicated in the pathophysiology of multiple sclerosis. An essential part of this axis, is the intestinal barrier and gastrointestinal disorders with intestinal barrier dysregulation appear to be linked to CNS demyelination, and hence involved in the etiopathogenesis of multiple sclerosis (MS). OBJECTIVE: The aim of this study was to evaluate the integrity of the intestinal barrier in patients with clinically definite multiple sclerosis (CDMS) and clinically isolated syndrome (CIS) using two serum biomarkers, claudin-3 (CLDN3), a component of tight epithelial junctions, and intestinal fatty acid binding protein (I-FABP), a cytosolic protein in enterocytes. METHODS: Serum levels of CLDN3 in 37 MS patients and 22 controls, and serum levels of I-FABP in 46 MS patients and 51 controls were measured using commercial ELISA kits. Complete laboratory tests excluded the presence of gluten-related disorders in all subjects. Thirty MS patients received either disease-modifying drugs (DMD), immunosuppression (IS) or corticosteroid treatment. RESULTS: CLDN3 levels were only significantly higher in the MS patients treated with DMD or IS compared to the control group (P=0.006). There were no differences in I-FABP serum levels between the groups. Serum CLDN3 levels did not correlate with serum I-FABP levels in CDMS, in CIS patients or controls. CONCLUSIONS: In multiple sclerosis patients, the intestinal epithelium may be impaired with increased permeability, but without significant enterocyte damage characterized by intracellular protein leakage. Based on our data, CLDN3 serum levels appear to assess intestinal dysfunction in MS patients but mainly in treated ones.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a claudin-3 $x metabolismus $7 D062465
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a roztroušená skleróza $x patofyziologie $x metabolismus $x krev $7 D009103
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a permeabilita $7 D010539
- 650 12
- $a proteiny vázající mastné kyseliny $x krev $7 D050556
- 650 12
- $a biologické markery $x krev $7 D015415
- 650 _2
- $a střevní sliznice $x metabolismus $7 D007413
- 650 _2
- $a studie případů a kontrol $7 D016022
- 650 _2
- $a funkce střevní bariéry $7 D000095644
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Barilly, Pavla, $u Department of Neurology, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic $d 1987- $7 xx0332491
- 700 1_
- $a Štětkářová, Ivana, $d 1963- $u Department of Neurology, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic $7 xx0030376
- 700 1_
- $a Bartoš, Aleš $u Department of Neurology, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic $7 xx0028753
- 700 1_
- $a Nosková, Libuše $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic $7 xx0224705
- 700 1_
- $a Zimová, Denisa $u Department of Neurology, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic $7 xx0240113
- 700 1_
- $a Židó, Michal $u Department of Neurology, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic $7 xx0269356
- 700 1_
- $a Hoffmanová, Iva $u Department of Internal Medicine, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic $7 xx0101007
- 773 0_
- $w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1804-7521 $g Roč. 169, č. 1 (2025), s. 37-43
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37581230 $y Pubmed
- 910 __
- $a ABA008 $b A 1502 $c 958 $y p $z 0
- 990 __
- $a 20250411 $b ABA008
- 991 __
- $a 20250522101936 $b ABA008
- 999 __
- $a ok $b bmc $g 2324862 $s 1246064
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 169 $c 1 $d 37-43 $e 20230811 $i 1804-7521 $m Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $n Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub $x MED00012606
- LZP __
- $b NLK124 $a Pubmed-20250411